المؤلفون: Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls

المصدر: Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2044-5385

URL الوصول: https://doaj.org/article/71614de5d82b474e855269ada1ea2dee

المؤلفون: Löwenberg, Bob, Beck, Joachim, Graux, Carlos, van Putten, Wim, Schouten, Harry C., Verdonck, Leo F., Ferrant, Augustin, Sonneveld, Pieter, Jongen-Lavrencic, Mojca, von Lilienfeld-Toal, Marie, Biemond, Bart J., Vellenga, Edo, Breems, Dimitri, de Muijnck, Hilde, Schaafsma, Ron, Verhoef, Gregor, Döhner, Hartmut, Gratwohl, Alois, Pabst, Thomas, Ossenkoppele, Gert J., Maertens, Johan, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German Austrian AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)

المصدر: In Blood 1 April 2010 115(13):2586-2591

المؤلفون: Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J, Schouten, Harry C, Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E, de Weerdt, Okke, Legdeur, Marie-Cecile J C, Kuball, Juergen, Kooy, Marinus van Marwijk, Gjertsen, Bjorn T, Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A, van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A, Chalandon, Yves, Passweg, Jakob, Valk, Peter J M, Manz, Markus G, Ossenkoppele, Gert J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

المساهمون: MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, CCA - Cancer Treatment and quality of life, Hematology, University of Zurich, Löwenberg, Bob, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), CCA - Cancer Treatment and Quality of Life, Clinical Haematology

المصدر: Löwenberg, B, Pabst, T, Maertens, J, Van Norden, Y, Biemond, B J, Schouten, H C, Spertini, O, Vellenga, E, Graux, C, Havelange, V, De Greef, G E, De Weerdt, O, Legdeur, M C J C, Kuball, J, Van Marwijk Kooy, M, Gjertsen, B T, Jongen-Lavrencic, M, Van De Loosdrecht, A A, Van Lammeren-Venema, D, Hodossy, B, Breems, D A, Chalandon, Y, Passweg, J, Valk, P J M, Manz, M G & Ossenkoppele, G J 2017, ' Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML ', Blood, vol. 129, no. 12, pp. 1636-1645 . https://doi.org/10.1182/blood-2016-10-740613
Blood, 129(12), 1636-1645. The American Society of Hematology
Blood, 129(12), 1636-1645. American Society of Hematology
Blood, 129(12), 1636-1645. AMER SOC HEMATOLOGY
Blood, Vol. 129, No 12 (2017) pp. 1636-1645
Blood, 129(12), 1636. American Society of Hematology

مصطلحات موضوعية: 1303 Biochemistry, PROGNOSIS, medicine.medical_treatment, 2720 Hematology, Hematopoietic stem cell transplantation, Gastroenterology, Biochemistry, RECOMMENDATIONS, 1307 Cell Biology, 0302 clinical medicine, Clofarabine, 610 Medicine & health, ddc:616, Adenine Nucleotides, Remission Induction, Induction Chemotherapy, Hematology, Middle Aged, CHEMOTHERAPY, Chemotherapy regimen, CYTARABINE, Survival Rate, Leukemia, Myeloid, Acute, 030220 oncology & carcinogenesis, SURVIVAL, Nucleophosmin, medicine.drug, Adult, Risk, medicine.medical_specialty, Antimetabolites, Antineoplastic, Adolescent, Gemtuzumab ozogamicin, Immunology, ACUTE MYELOID-LEUKEMIA, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Journal Article, Humans, Survival rate, Aged, Chemotherapy, 2403 Immunology, OLDER PATIENTS, business.industry, Myelodysplastic syndromes, Cell Biology, medicine.disease, GEMTUZUMAB OZOGAMICIN, Surgery, Consolidation Chemotherapy, 10032 Clinic for Oncology and Hematology, Cytarabine, Arabinonucleosides, business, 030215 immunology

وصف الملف: image/pdf; 1636.full.pdf - application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35dd14e23351c401ac01cdebbd8c234c
https://doi.org/10.1182/blood-2016-10-740613

المؤلفون: Tettero JM; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Al-Badri WKW; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Ngai LL; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Bachas C; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Breems DA; Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium., van Elssen CHMJ; Department of Internal Medicine, Division of Hematology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands., Fischer T; Department of Hematology and Oncology, Otto von Guericke University Hospital Magdeburg, Magdeburg, Germany., Gjertsen BT; Department of Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway., van Gorkom GNY; Department of Internal Medicine, Division of Hematology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands., Gradowska P; The Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) Data Center, Department of Hematology, Erasmus Medical Center (MC) Cancer Institute, Rotterdam, Netherlands., Greuter MJE; Department of Epidemiology and Data Science, Amsterdam Univerisity Medical Centers, location Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Griskevicius L; Hematology, Oncology, Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos and Vilnius University, Vilnius, Lithuania., Juliusson G; Department of Hematology, Skanes University Hospital, Lund, Sweden., Maertens J; Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium., Manz MG; Department of Medical Oncology and Hematology, University Hospital, Zurich, Switzerland.; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Pabst T; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.; Department of Medical Oncology, Inselspital, University Hospital, Bern, Switzerland., Passweg J; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.; Department of Hematology, University Hospital, Basel, Switzerland., Porkka K; Department of Hematology, Helsinki University Hospital Cancer Center, Helsinki, Finland., Löwenberg B; Department of Hematology, Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Janssen JJWM; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands., Cloos J; Department of Hematology, Amsterdam Univerisity Medical Centers location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, Netherlands.

المصدر: Frontiers in oncology [Front Oncol] 2022 Oct 10; Vol. 12, pp. 999822. Date of Electronic Publication: 2022 Oct 10 (Print Publication: 2022).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

المؤلفون: Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research: Daniel den Hoed Cancer Center Rotterdam, The Netherlands. lowenberg@haed.azr.nl, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E, Ossenkoppele GJ, Huijgens PC, Verdonck LF, van der Lelie J, Wielenga JJ, Schouten HC, Gmür J, Gratwohl A, Hess U, Fey MF, van Putten WL

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 1997 Dec; Vol. 15 (12), pp. 3496-506.

نوع المنشور: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Print ISSN: 0732-183X (Print) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Granulocyte-Macrophage Colony-Stimulating Factor/*administration & dosage , Leukemia, Myeloid/*drug therapy, Acute Disease ; Adolescent ; Adult ; Blood Cell Count ; Disease-Free Survival ; Evaluation Studies as Topic ; Female ; Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects ; Humans ; Male ; Middle Aged ; Remission Induction ; Time Factors ; Treatment Outcome